Rtj , referring back to 2005/2006 you may have attended a Cbio agm after the results from the first RA trials.Spectacular they were.I heard a story that one of the patients in the trial who had been wheel chair bound for some years (all fingers were disjointed and frozen from arthritis and could not walk).
The improvement in their condition after several weeks of treatment was amazing.Arriving for one of their bi weekly IV infusions this patient walked unaided down the hospital corridor arms out stretched wriggling their fingers.
It was at this meeting we were told we were all going to be very wealthy-the figure of $2B was mentioned and major pharmas were clamouring for cpn 10.
The Pharmas did their due diligence and walked away.This was due to shortcuts to save money ,and the many protocols that needed to be followed were not.One being animal safety trials to determine safe limits for Xtoll (inv 103) were not conducted prior to human trials.This ended up costing big time in additional funding requirements and about 2 years of wasted time.It is surprising and virtually unheard of in Biotech that Cbio never had a chief medical officer.
So my thoughts on where we are going from here are similar to yours.Having attended last years agm ,CMO Dr Mitchell Glass stated that in his whole career he has not seen or been approached with so much interest.I believe this is a big statement.I also think discussions were happening way before the agm.
Dr Glass also mentioned at the R&D Global Investment Conference Sept last year that the science behind Invion’s products were so compelling that he had to put the harness on again.
Where to from here –I believe a deal will be completed very soon (this takes some time with due diligence and plenty of argybargy) In my opinion, this will incorporate inv102 103 and 104. as inv 102 and 103 have multiple applications I don’t think a potential partner would want some of the applications of these drug’s going elsewhere..
The potential partner would fund ongoing trials for all indications maybe with the exception of Asthma which is already funded.Cystic fibrosus is gearing up this year for trials next year.
When an announce is made I believe with the calibre of our board and products (and the partner)-the market will certainty take note.
IVX Price at posting:
9.6¢ Sentiment: ST Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)